News

Evidence Mounts for Early Treatment of Smoldering Myeloma

Publish date: January 3, 2012

 

FROM THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY

Dr. Mateos reported receiving honoraria from Celgene, Millennium Pharmaceuticals, and Janssen. A coauthor reported receiving honoraria from Celgene and Janssen, and four coauthors reported employment with Celgene, the maker of lenalidomide. Dr. Beksac reported receiving honoraria from and serving as a speaker for Celgene and Janssen-Cilag.

Pages

Recommended Reading

Factors Predict Contralateral Breast Cancer Risk in BRCA Carriers
MDedge Internal Medicine
Breast Cancer Linked to Benign Thyroid Disease
MDedge Internal Medicine
Meta-Analysis: Pregnancy-Associated Breast Cancer Fares Poorly
MDedge Internal Medicine
Recent Diabetes Increases Breast Cancer Risk
MDedge Internal Medicine
Acupuncture Flops as Relief for Muscle Pain From Aromatase Inhibitors
MDedge Internal Medicine
Vitamin D Deficiency/Breast Cancer Link Questioned
MDedge Internal Medicine
Return ED Visits by Sickle Cell Patients Common
MDedge Internal Medicine
Iron Deficiency Anemia 'Unintended Consequence' of Gastric Bypass
MDedge Internal Medicine
Bevacizumab Effective With First-Line Treatment for Ovarian Cancer
MDedge Internal Medicine
'Best Results' Yet for Poor-Prognosis Elderly With DLBCL
MDedge Internal Medicine

Related Articles